Научные статьи \ Прикладные науки. Медицина. Технология \ Mедицинские науки \ Патология. Клиническая медицина \ Заболевания дыхательной системы

Взаимосвязь FoxP3+ регуляторных т-клеток с активностью заболевания и уровнем антител при раннем ревматоидном артрите

Взаимосвязь FoxP3+ регуляторных т-клеток с активностью заболевания и уровнем антител при раннем ревматоидном артрите

Автор: Авдеева А.С., Рубцов Ю.П., Дыйканов Д.Т., Попкова Т.В., Насонов Е.Л.

Журнал: Научно-практическая ревматология @journal-rsp

Рубрика: Оригинальные исследования

Статья в выпуске: 3 т.55, 2017 года.

Бесплатный доступ

Цель - проанализировать взаимосвязь количества FoxP3+ регуляторных Т-клеток (Трег) с клинико-лабораторными показателями активности заболевания и уровнем антител в группе пациентов с ранним ревматоидным артритом (РА). Материал и методы. В исследование были включены 45 не получавших ранее терапии метотрексатом пациентов с ранним РА (критерии ACR/EULAR 2010 г.), в том числе 39 женщин; медиана возраста составила 52,0 [32,5; 57,5] года, длительность заболевания - 5 [4; 6] мес, DAS28 - 5,01 [4,18; 5,8]; 71,1% больных были позитивны по ревматоидному фактору (РФ) и 88,9% позитивны по антителам к циклическому цитруллинированному пептиду (АЦЦП). Относительное и абсолютное количество Трег (FoxP3+CD25+; CD152+surface; CD152+intracellular; FoxP3+CD127-; CD25+CD127-; FoxP3+ICOS+; FoxP3+CD154+; FoxP3+CD274+) определялось методом иммунофлюоресцентного окрашивания и многоцветной проточной цитофлюориметрии. Контрольную группу составили 20 здоровых доноров, сопоставимых по полу и возрасту с обследованными больными. Результаты и обсуждение. У 22 (48,9%) больных была высокая, у 20 (44,4%) - умеренная и у 3 (6,7%) - низкая активность патологического процесса по DАS28. У пациентов с ранним РА, по сравнению со здоровыми донорами, отмечалось более низкое процентное количество (ПК) FoxP3+CD25+ клеток, ПК и абсолютное содержание (абс.) FoxP3+ICOS+ клеток, ПК и абс. FoxP3+CD154+ и FoxP3+ CD274+ Т-клеток; pрег при раннем РА, что ассоциируется с более высокой активностью заболевания, наличием системных проявлений болезни, а также сопровождается гиперпродукцией антител.

Еще

Ранний ревматоидный артрит, активность заболевания, аутоантитела, регуляторные т-лимфоциты

Короткий адрес: https://sciup.org/14945818

IDR: 14945818   |   DOI: 10.14412/1995-4484-2017-245-251

The relationship of FoxP3+ T regulatory cells to disease activity and antibody levels in early rheumatoid arthritis

Objective: to analyze the relationship of the count of FoxP3+ T regulatory cells (Tregs) to the clinical and laboratory parameters of disease activity and the levels of antibodies in a group of patients with early rheumatoid arthritis (RA). Subjects and methods. The investigation enrolled 45 patients with early RA (2010 ACR/EULAR criteria) who had not previously received treatment with methotrexate, including 39 women; median age was 52.0 [32.5; 57.5] years; disease duration, 5 [4; 6] months, DAS28 5.01 [4.18; 5.8]; 71.1% of the patients were rheumatoid factor (RF) positive and 88.9% were anti-cyclic citrullinated peptide positive. The relative and absolute counts of Treg (FoxP3+CD25+; CD152+surface; CD152+intracellular; FoxP3+CD127-; CD25+CD127-; FoxP3+ICOS+; FoxP3+CD154+; FoxP3+CD274+) were measured by immunofluorescence staining and multicolor flow cytometry. A control group consisted of 20 healthy donors who were matched for sex and age with the examined patients. Results and discussion. DАS28 was high, moderate, and low in 22 (48.9%), 20 (44.4%), and 3 (6.7%) patients, respectively. As compared with the healthy donors, the patients with early RA were observed to have lower values in the percentage of FoxP3+CD25+ cells, in the percentage and absolute count of FoxP3+ICOS+ cells, in the percentage and absolute count of FoxP3+CD154+ and FoxP3+ CD274+ T cells; preg were decreased in early RA, which is associated with higher disease activity, the systemic manifestations of the disease and which is also accompanied by antibody hyperproduction.

Еще

Список литературы Взаимосвязь FoxP3+ регуляторных т-клеток с активностью заболевания и уровнем антител при раннем ревматоидном артрите

  • Быковская СН, Насонов ЕЛ. Роль дефектов иммуносупрессии в развитии аутоиммунных заболеваний. Научно-практическая ревматология. 2005;43(4):81-4
  • Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T Cells and immune tolerance. Cell. 2008;133(5):775-87 DOI: 10.1016/j.cell.2008.05.009
  • Zeng H, Chi H. The interplay between regulatory T cells and metabolism in immune regulation. OncoImmunology. 2013;2(11):e26586. Epub 2013 Oct 21 DOI: 10.4161/onci.26586
  • Lahl K, Loddenkemper C, Drouin C, et al. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med. 2007;204(1):57-63. Epub 2007 Jan 2 DOI: 10.1084/jem.20061852
  • Buckner JH. Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10:849-59 DOI: 10.1038/nri2889
  • Wildin RS, Freitas A. IPEX and FOXP3: clinical and research perspectives. J Autoimmun. 2005;25 Suppl:56-62 DOI: 10.1016/j.jaut.2005.04.008
  • Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология: Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290-331
  • Firestein G. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356-61 DOI: 10.1038/nature01661
  • Cope A. T cells in rheumatoid arthritis. Arthr Res Ther. 2008;10 Suppl 1:S1 DOI: 10.1186/ar2412
  • Choy E. Selective modulation of T cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009;27:510-8.
  • Steward-Tharp S, Song Y, Siegel R, O’Shea J. New insights into T cells biology and T cells directed therapy for autoimmunity inflammation and immunosuppression. Ann NY Acad Sci. 2010;1183:123-48 DOI: 10.1111/j.1749-6632.2009.05124.x
  • Cao D, Malmstrom V, Baecher-Allan C, et al. Isolation and functional characterization of regulatory CD25brightCD4+ T cells fromthe target organ of patients with rheumatoid arthritis. Eur J Immunol. 2003;33:215-23 DOI: 10.1002/immu.200390024
  • Cao D, van Vollenhoven R, Klareskog L, et al. CD25+CD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthr Res Ther. 2004;6:R335-R346 DOI: 10.1186/ar1192
  • Van Amelsfort JMR, Jacobs KMG, Bijlsma JWJ, et al. CD4+CD25+ regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 2004;50:2775-85 DOI: 10.1002/art.20499
  • Mottonen M, Heikkinen J, Mustonen L, et al. CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exper Immunol. 2005;140:360-7 DOI: 10.1111/j.1365-2249.2005.02754.x
  • Liu M-F, Wang C-R, Fung L-L, et al. The presence of cytokine-suppressive CD4+CD25+ T cells in the peripheral blood and synovial fluid of patients with rheumatoid arthritis. Scand J Immunol. 2005;62:312-7 DOI: 10.1111/j.1365-3083.2005.01656.x
  • Cao D, Borjesson O, Larsson P, et al. FOXP3 identifies regulatory CD25brightCD4+ T cells in rheumatic joints. Scand J Immunol. 2006;63:444-52 DOI: 10.1111/j.1365-3083.2006.001755.x
  • Jiao Z, Wang W, Jia R, et al. Accumulation of FoxP3-expressing CD4+CD25+ T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis. Scand J Rheumatol. 2007;36:428-33 DOI: 10.1080/03009740701482800
  • Moradi B, Schnatzer P, Hagmann S, et al. CD4+CD25+/highCD127low/-regulatory T cells are enriched in rheumatoid arthritis and osteoarthritis joints -analysis of frequency and phenotype in synovial membrane, synovial fluid and peripheral blood. Arthritis Res Ther. 2014;16: R97 DOI: 10.1186/ar4545
  • Dejaco C, Duftner C, Klauser A, Schirmer M. Altered T-cell subtypes in spondyloarthritis, rheumatoid arthritis and polymyalgia rheumatic. Rheumatol Int. 2010;30:297-303 DOI: 10.1007/s00296-009-0949-9
  • Sempere-Ortells JM, Perez-Garcia V, Marin-Alberca G, et al. Quantification and phenotype of regulatory T cells in rheumatoid arthritis according to disease activity Score-28. Autoimmunity. 2009;42:636-45 DOI: 10.3109/08916930903061491
  • Kawashiri S-Y, Kawakami A, Okada A, et al. CD4+CD25(high)CD127(low/-) Treg cell frequency from peripheral blood correlates with disease activity in patients with rheumatoid arthritis. J Rheumatol. 2011;38:2517-21 DOI: 10.3899/jrheum.110283
  • Han GM, O’Neil-Andersen NJ, Zurier RB, Lawrence DA. CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. Cell Immunol. 2008;253:92-101 DOI: 10.1016/j.cellimm.2008.05.007
  • Lin SC, Chen K-H, Lin C-H, et al. The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients. Eur J Clin Invest. 2007;37:987-96 DOI: 10.1111/j.1365-2362.2007.01882.x
  • Ji L, Geng Y, Zhou W, Zhang Z. A study on relationship among apoptosis rates, number of peripheral T cell subtypes and disease activity in rheumatoid arthritis. Int J Rheum Dis. 2016;19:167-71 DOI: 10.1111/1756-185X.12211
  • Dombrecht EJ, Aerts NE, Schuerwegh AJ, et al. Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis. Clin Exper Rheumatol. 2006;24:31-7.
  • Lawson CA, Brown AK, Bejarano V, et al. Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood. Rheumatology (Oxford). 2006;45(10):1210-7 DOI: 10.1093/rheumatology/kel089
  • Hensor RMA, Hunt L, Patmar R, et al. Predicting the evaluation of inflammatory arthritis in ACPA-positive individuals: can T-cell subset help? Ann Rheum Dis. 2014;73 Suppl 1:A14 DOI: 10.1136/annrheumdis-2013-205124.32
  • Ehrenstein MR, Evans JG, Singt A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFa therapy. J Exp Med. 2004;200(3):277-85. Epub 2004 Jul 26 DOI: 10.1084/jem.20040165
  • McGovern JL, Nguyen DX, Notley CA, et al. Th17 cells are restarained by T reg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum. 2012;64(10):3129-38 DOI: 10.1002/art.34565
  • Wehrens EJ, Mijnheer G, Duurland CL, et al. Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-akt hyperactivation in effector cells. Blood. 2011;118:3538-48 DOI: 10.1182/blood-2010-12-328187
  • Raptopoulou AP, Bertsias G, Makrygiannakis D, et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 2010;62:1870-80 DOI: 10.1002/art.27500
  • Behrens F, Himsel A, Rehart S, et al. Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritis. Ann Rheum Dis. 2007;66:1151-6 DOI: 10.1136/ard.2006.068320
  • Kim CH, Rott LS, Clark-Lewis I, et al. Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells. J Exp Med. 2001;193:1373-81 DOI: 10.1084/jem.193.12.1373
  • Odegard JM, Marks BR, DiPlacido LD, et al. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J Exp Med. 2008;205:2873-86 DOI: 10.1084/jem.20080840
  • Radbruch A, Muehlinghaus G, Luger EO, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol. 2006;6:741-50 DOI: 10.1038/nri1886
  • Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral Immunity due to long-lived plasma cells. Immunity. 1998;8:363-72 DOI: 10.1016/S1074-7613(00)80541-5
  • Hoyer BF, Moser K, Hauser AE, et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/Wmice. J Exp Med. 2004;199:1577-84 DOI: 10.1084/jem.20040168
  • Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 2003;48:1484-92 DOI: 10.1002/art.10947
  • Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood. 2006;107:3925-32 DOI: 10.1182/blood-2005-11-4502
  • Iikuni N, Lourenco EV, Hahn BH, La Cava A. Cutting edge: regulatory T cells directly suppress B cells in systemic lupus erythematosus. J Immunol. 2009;183:1518-22 DOI: 10.4049/jim-munol.0901163
  • Grossman WJ, Verbsky JW, Barchet W, et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004;21:589-601 DOI: 10.1016/j.immu-ni.2004.09.002
  • Seo SJ, Fields ML, Buckler JL, et al. The impact of T helper and T regulatory cells on the regulation of anti-double stranded DNA B cells. Immunity. 2002;16:535-46 DOI: 10.1016/S1074-7613(02)00298-4
  • Morgan ME, Sutmuller RP, Witteveen HJ, et al. CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum. 2003;48:1452-60 DOI: 10.1002/art.11063
  • Jang E, Cho W, Cho M, et al. Foxp3+ Regulatory T Cells Control Humoral Autoimmunity by Suppressing the Development of Long-Lived Plasma Cells. J Immunol. 2011;186:1546-53 DOI: 10.4049/jimmunol.1002942
  • Hunt L, Hensor EM, Nam J, et al. T cell subsets: an immunological biomarker to predict progression to clinical arthritis in ACPA-positive individuals. Ann Rheum Dis. 2016;75:1884-9 DOI: 10.1136/annrheumdis-2015-207991
  • Janssen K, Westra J, Chalan P, et al. Regulatory CD4+ T-Cell Subsets and AntiCitrullinated Protein Antibody Repertoire: Potential Biomarkers for Arthritis Development in Seropositive Arthralgia Patients? PLoS ONE 2016;11(9):e0162101 DOI: 10.1371/journal.pone.0162101PLoS
Еще
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp